Enzolytics (ENZC) Stock Price, News & Analysis

Company Overview

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.

Key Stats

• Today's Range: $0.0009 to $0.0012
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 10.17 million shs
• Average Volume: 11.05 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENZC Stock Analysis - Frequently Asked Questions

How have ENZC shares performed this year?

Enzolytics' stock was trading at $0.0175 at the beginning of the year. Since then, ENZC shares have decreased by 94.3% and is now trading at $0.0010.
View the best growth stocks for 2024 here.

How do I buy shares of Enzolytics?

Shares of ENZC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Enzolytics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzolytics investors own include HUMBL (HMBL), Bionano Genomics (BNGO), Artificial Intelligence Technology Solutions (AITX), Meta Platforms (META), SNDL (SNDL), Tesla (TSLA).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Entertainment
• Current Symbol: OTCMKTS:ENZC
• CUSIP: N/A
• CIK: N/A
• Web: enzolytics.com
• Phone: (972) 292-9414
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A